The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.20
Ask: 3.30
Change: 0.00 (0.00%)
Spread: 0.10 (3.125%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS UPDATES: ValiRx reports narrowed loss; McBride revenue slips

Tue, 07th Sep 2021 15:05

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

ValiRx PLC - life science company - Reports narrowed pretax loss of GBP785,434 for the six months to the end of June versus GBP884,523 posted a year before. ValiRX says its administrative expenses reduced to GBP618,228 from GBP791,866 a year earlier, but research & developments costs rose to GBP166,500 from GBP99,879. "I look forward to continued progress with our existing projects and the opportunity to build on our concept of connected innovation," says Non-Executive Chair Kevin Cox.

----------

McBride PLC - domestic household products manufacturer - Reports revenue decline of 3.4% for the year to the end of June to GBP682.3 million from GBP706.2 million posted in financial 2020. On a constant currency basis, revenue falls by 4.0% year-on-year. Pretax profit, however, climbs to GBP11.3 million from GBP11.2 million the year prior amid reduction in administrative costs to GBP165.2 million from GBP168.3 million. McBride reviews its dividend policy as part of its strategy reset, with no final dividend proposed, unchanged year-on-year. "We continue to anticipate a weak first half year, especially when compared to our strong first half last year, with profits therefore heavily weighted to the second half of the year," says Chief Executive Chris Smith.

----------

Alumasc Group PLC - building products supplier - Reports 19% growth in revenue from continuing operations to GBP90.5 million for the financial year to June 30 from GBP76.0 million the year ago. Pretax profit, meanwhile, jumps to GBP9.8 million from GBP2.7 million year-on-year. The company declares final dividend of 6.25 pence a share, taking a full-year payout to 9.5p, up from 2.0p paid the year before. "I am delighted to report this excellent set of results to our shareholders and believe Alumasc is well-positioned to benefit from the long-term growth drivers in our market," says CEO Paul Hooper.

----------

DP Eurasia NV - Netherlands-based pizza delivery company - Reports system sales for the six months to June 30 of TRY1.05 billion, about GBP91.5 million, up 58% year-on-year. System sales like-for-like growth totals 18% in the half year. Revenue rises by 50% to TRY658.0 million. Full year guidance for Turkey like-for-like raised to 35% - 40% from 21% - 25% guided previously, and adjusted earnings before interest, tax, depreciation and amortisation expected to be slightly ahead of current market expectations, the company notes. "Digital continues to be the driving force behind our sales with the digital mix in delivery reaching record levels in both Turkey and Russia for the first half of the year," says CEO Aslan Saranga. Online delivery system sales as a share of delivery system sales stood at 78% for the half year, rising from 75% a year before.

----------

Luceco PLC - LED lighting manufacturer and distributor - Posts revenue growth of 51% for the six months to the end of June to GBP108.2 million from GBP71.6 million recorded a year earlier. On a constant currency basis, revenue is up 58% year-on-year. Pretax profit almost doubles to GBP16.6 million from GBP8.4 million the year prior. Luceco declares dividend of 2.6p a share, up from 1.5p paid the year before. "The group has outperformed the market throughout its history thanks to its leading brands, strong channel relationships, well-invested product innovation and operational agility. The competitive advantages of our business model have been accentuated during Covid, accelerating our market share gains," says CEO John Hornby.

----------

GRC International Group PLC - supplier of cyber security, risk management and compliance products - Reports revenue for the financial year to March 31 down 16% to GBP11.8 million from GBP14.1 million due to the pandemic. However, pretax loss narrowed to GBP2.8 million from GBP3.7 million year-on-year. This is due to a reduction in total administrative expenses to GBP8.9 million from GBP11.6 million the year prior. Going forward, the company says positive performance seen in the final quarter of its financial 2021 continued into the first quarter of its current financial year.

----------

EPE Special Opportunities Ltd - investment firm - Reports net asset value per share of 542.30p as at July 31e, representing an increase of 24% on the NAV per share of 437.63p as at January 31. The share price stood at 393.00p at the end of July, representing an increase of 45% on the share price of 271.00p as at the end of January. "The performance of the company in the six months ended July 31 was strong despite the ongoing disruption caused by the Covid-19 pandemic. The company has continued to make progress in the existing portfolio and has successfully completed a new investment in the period," says Chair Clive Spears.

----------

RA International Group PLC - remote site services provider - Reports revenue of USD26.2 million for the six months to the end of June, down from USD35.4 million posted the year earlier. Pretax profit declined to USD800,000 from USD1.6 million year-on-year. "We are cautiously optimistic and starting to see encouraging signs that the business environment is improving; depending on timing, this could boost our second half performance, but in any event should bridge to a stronger 2022," says CEO Soraya Narfeldt.

Separately, RA International reports the award of a new contract in a joint venture with ECC, the US based global construction and environmental remediation contractor. The contract with US Navy facilities engineering systems command far east is a five year contract for design and construction services supporting their base on the island of Diego Garcia in the Indian Ocean. The contract ceiling for this award is USD249 million and RA International and ECC will compete for individual task orders with four other awardees.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
10 Feb 2020 16:00

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
14 Jan 2020 14:50

ValiRx signs letter of intent in a bid to fund VAL401

(Sharecast News) - Clinical-stage biotechnology company ValiRx updated the market on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401 on Tuesday.

Read more
14 Jan 2020 11:08

ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding

ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding

Read more
6 Jan 2020 09:59

ValiRx Raises GBP200,000 To Progress Product Development

ValiRx Raises GBP200,000 To Progress Product Development

Read more
16 Dec 2019 10:17

ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients

ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients

Read more
28 Nov 2019 16:13

ValiRx granted US patent for 'VAL201' compound

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Thursday that the US Patent and Trademark Office has granted patent number 10,400,008, titled 'Modulators Of The SRC-Kinase Activity For Preventing Or Treating Metastatic Cancer', to its lead therapeutic compound 'VAL201'.

Read more
28 Nov 2019 15:57

ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment

ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment

Read more
14 Oct 2019 13:44

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

Read more
26 Sep 2019 11:43

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

Read more
24 Sep 2019 12:40

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

Read more
10 Sep 2019 13:45

ValiRx Prostate Cancer Drug VAL201 Still Meeting Endpoints

(Alliance News) - ValiRx PLC on Tuesday said its VAL201 lead compound is still meeting all of its published endpoints and is behaving as expected in prostate cancer.VAL201 has been as a and

Read more
1 Aug 2019 12:01

ValiRx Granted European Patent Allowance For VAL301 Compound

(Alliance News) - Clinical stage biotechnology firm ValiRx PLC said Thursday it has been granted a patent notice of allowance for its pre-clinical therapeutic compound, VAL301, from the European a

Read more
23 Jul 2019 16:25

Monecor Takes Nearly 6% Holding In Biotechnology Firm ValiRx

(Alliance News) - ValiRx PLC on Tuesday said Monecor London Ltd now holds 5.7% interest in the biotechnology company.Prior to this transaction on Monday, Monecor's holding totalled were

Read more
26 Jun 2019 14:30

US Grands Patent Claim For valiRx's VAL201 In Metastatic Cancer

(Alliance News) - ValiRx PLC on Wednesday said the US has allowed a patent claim for the use of VAL201 in metastatic cancer.Shares in ValiRx were down 7.1% at 0.21 pence in afternoon trade

Read more
26 Jun 2019 10:53

ValiRx gets US patent protection for use of VAL201 peptide

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Wednesday that the US Patent and Trademark Office (USPTO) has allowed patent claims directed towards a method of preventing the worsening of symptoms of metastatic cancer, reducing the progression of metastatic cancer, or treating metastatic cancer - including prostate cancer - by administration of the 'VAL201' peptide.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.